Monitoring treatment response in acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how well the combination of azacitidine and venetoclax works for people with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. The trial measures a microscopic sign of cancer called measurable residual disease (MRD) to see how the treatment affects survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a new diagnosis of acute myeloid leukemia (AML) that has not been treated yet (except for hydroxyurea, a medicine that lowers high white blood cell counts).
- Your doctor must be planning to treat you with the combination of azacitidine and venetoclax.
- You must not be eligible for intensive chemotherapy, meaning your health does not allow for a stronger treatment.
- You must have a bone marrow sample that can be tested for a special marker called measurable residual disease (MRD).
- Your AML must not involve the brain or spinal fluid.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of two drugs, chidamide and azacitidine (AZA), can help people with acute myeloid leukemia (AML) who still have small amounts of leukemia cells (called MRD) after a stem cell transplant. The goal is to see if this treatment can clear those leftover cells and lower the chance of the leukemia coming back.
This trial tests a combination of two drugs, azacitidine and venetoclax, for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells left (measurable residual disease). The goal is to see if this treatment can clear those remaining cells before a stem cell transplant.
This study tests whether adding venetoclax to azacitidine after a patient reaches remission helps keep the leukemia from coming back. It is for people with acute myeloid leukemia (AML) who have completed initial treatment and are in their first remission.
This study looks at how the drug venetoclax works in people newly diagnosed with acute myeloid leukemia (AML). It helps doctors understand the right dose for better results.
This study looks at how a standard AML treatment plan affects a person’s disease status over time. It focuses on newly diagnosed adults who cannot safely get intensive chemotherapy, using oral venetoclax plus azacitidine.
This early-phase trial tests whether azacitidine (CC-486) plus venetoclax can help people with acute myeloid leukemia (AML) that is not APL. It’s designed to find safe dosing and see how well the combination works for newly diagnosed or relapsed/refractory AML.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.